Arcutis Biotherapeutics Quarterly Income Statement
NASDAQ: ARQTHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcutis Biotherapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Arcutis Biotherapeutics generated $129.9 million in revenue, up 59.3% from the same quarter a year earlier. Net income was $15.0 million, for a net margin of 11.6% versus a median of -10.7% in the prior 5 quarters. Gross margin was 91.6% (up from 90.8%) and operating margin 12.7%.
Diluted earnings per share came in at $0.11.
Summary generated from market data by MetaCap's automated system. Methodology
Arcutis Biotherapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.86M | 105.40M | 129.50M | 99.22M | 81.50M | 65.85M | 71.36M | 44.76M | 30.86M | 49.57M | 13.53M | 38.11M |
| Revenue growth (YoY) | +59.33% | +60.07% | +81.48% | +121.69% | +164.13% | +32.84% | +427.58% | +17.44% | +494.57% | +1682.42% | +356.81% | +5156.41% |
| Cost of Revenue | 10.94M | 9.78M | 11.69M | 8.69M | 7.49M | 8.83M | 6.91M | 5.50M | 3.46M | 3.26M | 2.25M | 1.18M |
| Gross Profit | 118.92M | 95.61M | 117.81M | 90.53M | 74.01M | 57.02M | 64.45M | 39.25M | 27.39M | 46.31M | 11.28M | 36.93M |
| Operating Expenses | 102.49M | 104.70M | 99.43M | 82.01M | 88.62M | 81.55M | 72.09M | 78.32M | 77.47M | 77.94M | 72.45M | 75.01M |
| Research & Development | 20.36M | 30.63M | 20.45M | 19.60M | 19.45M | 17.54M | 14.48M | 19.50M | 19.30M | 23.14M | 23.77M | 26.24M |
| Selling, General & Admin | 82.14M | 74.08M | 78.98M | 62.40M | 69.17M | 64.00M | 57.61M | 58.82M | 58.17M | 54.79M | 48.67M | 47.59M |
| Operating Income | 16.43M | -9.09M | 18.39M | 8.53M | -14.61M | -24.53M | -7.63M | -39.07M | -50.08M | -31.62M | -61.17M | -36.90M |
| Interest Expense | 3.41M | 4.37M | 3.00M | 3.07M | 3.03M | 2.98M | 5.55M | 6.65M | 7.48M | 7.48M | 7.76M | 7.56M |
| Other Income (Expense) | -1.28M | -20.00K | -6.42M | 2.04M | -933.00K | 193.00K | -13.41M | 4.18M | 5.23M | 4.04M | -9.85M | 2.72M |
| Income Tax | 136.00K | 93.00K | 470.00K | 80.00K | 342.00K | 279.00K | 323.00K | 0 | 0 | 324.00K | 25.00K | 3.02M |
| Net Income | 15.01M | -11.29M | 17.39M | 7.41M | -15.89M | -25.06M | -10.79M | -41.54M | -52.33M | -35.38M | -66.28M | -44.77M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 0.11 | -0.09 | 0.14 | 0.06 | -0.13 | -0.20 | -0.09 | -0.33 | -0.42 | -0.32 | -0.58 | -0.73 |
| EPS (Diluted) | 0.11 | -0.09 | 0.14 | 0.06 | -0.13 | -0.20 | -0.09 | -0.33 | -0.42 | -0.32 | -0.58 | -0.73 |
| Shares Outstanding (Basic) | 130.52M | 129.37K | — | 127.62M | 127.00M | 126.04K | — | 124.30M | 123.48M | 111.05M | — | 61.73M |
| Shares Outstanding (Diluted) | 135.90M | 129.37K | — | 132.88M | 127.00M | 126.04K | — | 124.30M | 123.48M | 111.05M | — | 61.73M |
| EBITDA | — | — | — | — | — | -24.38M | -7.53M | -38.91M | -49.91M | -31.45M | -60.94M | -36.70M |
| Gross Margin | 91.58% | 90.72% | 90.97% | 91.25% | 90.81% | 86.59% | 90.32% | 87.70% | 88.77% | 93.43% | 83.39% | 96.90% |
| Operating Margin | 12.65% | -8.62% | 14.20% | 8.59% | -17.93% | -37.25% | -10.70% | -87.29% | -162.28% | -63.79% | -452.23% | -96.84% |
| Net Margin | 11.56% | -10.72% | 13.43% | 7.47% | -19.49% | -38.06% | -15.12% | -92.81% | -169.59% | -71.38% | -490.05% | -117.47% |
This table shows 12 quarterly periods of Arcutis Biotherapeutics's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ARQT's reporting calendar. What is a income statement?